The Public Citizen calls for an independent review of the raw data from clinical trials funded by Tamiflu’s maker, Roche. The company has claimed that the drug dramatically reduced hospital admissions as well as bronchitis and pneumonia. But a recent investigation by British TV has concluded that such claims were false. Public Citizen claims that the clinical research conducted on the effectiveness of Tamiflu has been funded by the drug’s manufacturer Roche. The Authors conclude that we “have no confidence in claims that (Tamiflu) reduces that risk of complications and hospital admission in people with influenza,” and they wrote that it should not be used in routine control of seasonal influenza.